Related references
Note: Only part of the references are listed.Antibodies to adalimumab are associated with future inflammation in Crohn's patients receiving maintenance adalimumab therapy: a post hoc analysis of the Karmiris trial
Filip Baert et al.
GUT (2016)
Clinical and demographic characteristics predictive of treatment outcomes for certolizumab pegol in moderate to severe Crohn's disease: analyses from the 7-year PRECiSE 3 study
W. J. Sandborn et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2015)
Randomised clinical trial: deep remission in biologic and immunomodulator naive patients with Crohn's disease - a SONIC post hoc analysis
J. -F. Colombel et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2015)
Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed
J. P. Gisbert et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2015)
Comparative Effectiveness of Immunosuppressants and Biologics for Inducing and Maintaining Remission in Crohn's Disease: A Network Meta-analysis
Glen S. Hazlewood et al.
GASTROENTEROLOGY (2015)
Trough Concentrations of Infliximab Guide Dosing for Patients With Inflammatory Bowel Disease
Niels Vande Casteele et al.
GASTROENTEROLOGY (2015)
Loss of Infliximab Into Feces Is Associated With Lack of Response to Therapy in Patients With Severe Ulcerative Colitis
Johannan F. Brandse et al.
GASTROENTEROLOGY (2015)
Role for Therapeutic Drug Monitoring During Induction Therapy with TNF Antagonists in IBD: Evolution in the Definition and Management of Primary Nonresponse
Konstantinos Papamichael et al.
INFLAMMATORY BOWEL DISEASES (2015)
Value of endoscopy and MRI for predicting intestinal surgery in patients with Crohn's disease in the era of biologics
A. Jauregui-Amezaga et al.
GUT (2015)
Systematic review with network meta-analysis: the efficacy of anti-TNF agents for the treatment of Crohn's disease
R. W. Stidham et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2014)
Adalimumab dose escalation is effective for managing secondary loss of response in Crohn's disease
C. Ma et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2014)
Adalimumab drug and antibody levels as predictors of clinical and laboratory response in patients with Crohn's disease
Y. Mazor et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2014)
Review article: why, when and how to de-escalate therapy in inflammatory bowel diseases
B. Pariente et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2014)
Optimizing anti-TNF treatments in inflammatory bowel disease
Shomron Ben-Horin et al.
AUTOIMMUNITY REVIEWS (2014)
Phenotypic Features of Crohn's Disease Associated With Failure of Medical Treatment
Gordon W. Moran et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2014)
Adalimumab Induces Deep Remission in Patients With Crohn's Disease
Jean-Frederic Colombel et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2014)
Association Between Plasma Concentrations of Certolizumab Pegol and Endoscopic Outcomes of Patients With Crohn's Disease
Jean-Frederic Colombel et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2014)
Early Trough Levels and Antibodies to Infliximab Predict Safety and Success of Reinitiation of Infliximab Therapy
Filip Baert et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2014)
Endoscopic and Medical Management of Fibrostenotic Crohn's Disease
Clara Thienpont et al.
DIGESTIVE DISEASES (2014)
Sa1264 Drug Trough Levels and Primary Nonresponse to antiTNF Therapy in Moderate-Severe Crohn Disease. Results of the Optimiza Study
Ana Echarri et al.
GASTROENTEROLOGY (2014)
Accuracy of Magnetic Resonance Enterography in Assessing Response to Therapy and Mucosal Healing in Patients With Crohn's Disease
Ingrid Ordas et al.
GASTROENTEROLOGY (2014)
Individualised therapy is more cost-effective than dose intensification in patients with Crohn's disease who lose response to anti-TNF treatment: a randomised, controlled trial
Casper Steenholdt et al.
GUT (2014)
Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial
Freddy Cornillie et al.
GUT (2014)
Patient Factors That Increase Infliximab Clearance and Shorten Half-life in Inflammatory Bowel Disease: A Population Pharmacokinetic Study
Iris Dotan et al.
INFLAMMATORY BOWEL DISEASES (2014)
Antibodies to Infliximab and Risk of Infusion Reactions in Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-analysis
Sorcha O'Meara et al.
INFLAMMATORY BOWEL DISEASES (2014)
Predictors of response to Infliximab in children with luminal Crohn's disease
Zubin Grover et al.
JOURNAL OF CROHNS & COLITIS (2014)
A matrix-based prediction model for primary response to infliximab in Crohn's disease patients
T. Billiet et al.
JOURNAL OF CROHNS & COLITIS (2014)
Simple endoscopic score for Crohn's disease (SES-CD) predicts long-term prognosis in Crohn's disease patients with clinical remission
M. Naganuma et al.
JOURNAL OF CROHNS & COLITIS (2014)
Systematic review: Histological remission in inflammatory bowel disease. Is 'complete' remission the new treatment paradigm? An IOIBD initiative
R. V. Bryant et al.
JOURNAL OF CROHNS & COLITIS (2014)
C-reactive protein is an indicator of serum infliximab level in predicting loss of response in patients with Crohn's disease
Toshifumi Hibi et al.
JOURNAL OF GASTROENTEROLOGY (2014)
Predicting complicated Crohn's disease and surgery: phenotypes, genetics, serology and psychological characteristics of a population-based cohort
J. D. Ryan et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2013)
Impact of Antibodies to Infliximab on Clinical Outcomes and Serum Infliximab Levels in Patients With Inflammatory Bowel Disease (IBD): A Meta-Analysis
Kavinderjit S. Nanda et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2013)
Metabolic Profiling Predicts Response to Anti-Tumor Necrosis Factor α Therapy in Patients With Rheumatoid Arthritis
Sabrina R. Kapoor et al.
ARTHRITIS AND RHEUMATISM (2013)
Addition of an Immunomodulator to Infliximab Therapy Eliminates Antidrug Antibodies in Serum and Restores Clinical Response of Patients With Inflammatory Bowel Disease
Shomron Ben-Horin et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2013)
Increased Body Mass Index Is Associated with Earlier Time to Loss of Response to Infliximab in Patients with Inflammatory Bowel Disease
Jason W. Harper et al.
INFLAMMATORY BOWEL DISEASES (2013)
Predictors of dose escalation of adalimumab in a prospective cohort of Crohn's disease patients
E. Bultman et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2012)
Long-term outcome of a third anti-TNF monoclonal antibody after the failure of two prior anti-TNFs in inflammatory bowel disease
P. S. A. de Silva et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2012)
C-reactive protein, an indicator for maintained response or remission to infliximab in patients with Crohn's disease: a post-hoc analysis from ACCENT I
W. Reinisch et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2012)
Efficacy and safety of infliximab and adalimumab in Crohn's disease: a single centre study
F. Zorzi et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2012)
Therapeutic Drug Monitoring of Tumor Necrosis Factor Antagonists in Inflammatory Bowel Disease
Ingrid Ordas et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2012)
Anti-TNF Monoclonal Antibodies in Inflammatory Bowel Disease: Pharmacokinetics-Based Dosing Paradigms
Ingrid Ordas et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2012)
Predictors of adalimumab dose escalation in patients with crohn's disease at a tertiary referral center
Russell D. Cohen et al.
INFLAMMATORY BOWEL DISEASES (2012)
Trough levels and antibodies to infliximab may not predict response to intensification of infliximab therapy in patients with inflammatory bowel disease
Benjamin Pariente et al.
INFLAMMATORY BOWEL DISEASES (2012)
Serological antibodies in inflammatory bowel disease: A systematic review
Lani Prideaux et al.
INFLAMMATORY BOWEL DISEASES (2012)
Fecal calprotectin concentration predicts outcome in inflammatory bowel disease after induction therapy with TNFα blocking agents
Pauliina Molander et al.
INFLAMMATORY BOWEL DISEASES (2012)
Efficacy, tolerability, and predictors of response to infliximab therapy for Crohn's disease: A large single centre experience
Michael B. Sprakes et al.
JOURNAL OF CROHNS & COLITIS (2012)
Current relevance of pharmacogenetics in immunomodulation treatment for Crohn's disease
Rebecca L. Roberts et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2012)
High-dose infliximab for treatment of pediatric ulcerative colitis: A survey of clinical practice
Roy Nattiv et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2012)
Prediction of Crohn's disease relapse with faecal calprotectin in infliximab responders: a prospective study
D. Laharie et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2011)
Review article: loss of response to anti-TNF treatments in Crohn's disease
S. Ben-Horin et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2011)
Early clinical remission and normalisation of CRP are the strongest predictors of efficacy, mucosal healing and dose escalation during the first year of adalimumab therapy in Crohn's disease
L. S. Kiss et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2011)
The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD With the European Crohn's and Colitis Organization: When to Start, When to Stop, Which Drug to Choose, and How to Predict Response
Geert R. D'Haens et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2011)
Loss of Response and Need for Adalimumab Dose Intensification in Crohn's Disease: A Systematic Review
Vincent Billioud et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2011)
Efficacy of Biological Therapies in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis
Alexander C. Ford et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2011)
Pharmacokinetic Properties of Infliximab in Children and Adults with Crohn's Disease: A Retrospective Analysis of Data from 2 Phase III Clinical Trials
Adedigbo A. Fasanmade et al.
CLINICAL THERAPEUTICS (2011)
The immunogenic part of infliximab is the F(ab ')(2), but measuring antibodies to the intact infliximab molecule is more clinically useful
Shomron Ben-Horin et al.
GUT (2011)
Endoscopic Monitoring of Infliximab Therapy in Crohn's Disease
Clas-Goran af Bjorkesten et al.
INFLAMMATORY BOWEL DISEASES (2011)
Development of a new Immunoassay for the accurate determination of anti-infliximab antibodies in Crohn's Disease
Hirotsugu Imaeda et al.
INFLAMMATORY BOWEL DISEASES (2011)
Dosage Adjustment During Long-term Adalimumab Treatment for Crohn's Disease: Clinical Efficacy and Pharmacoeconomics
William J. Sandborn et al.
INFLAMMATORY BOWEL DISEASES (2011)
Long-term Durability of Infliximab Treatment in Crohn's Disease and Efficacy of Dose Escalation in Patients Losing Response
Maria Chaparro et al.
JOURNAL OF CLINICAL GASTROENTEROLOGY (2011)
Adalimumab real-world dosage pattern and predictors of weekly dosing: Patients with Crohn's disease in the United States
Edward V. Loftus et al.
JOURNAL OF CROHNS & COLITIS (2011)
Adverse effects of biologics: a network meta-analysis and Cochrane overview
J. A. Singh et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2011)
Clinical Utility of Measuring Infliximab and Human Anti-Chimeric Antibody Concentrations in Patients With Inflammatory Bowel Disease
Waqqas Afif et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2010)
Increased Response and Remission Rates in Short-Duration Crohn's Disease With Subcutaneous Certolizumab Pegol: An Analysis of PRECiSE 2 Randomized Maintenance Trial Data
Stefan Schreiber et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2010)
Clinical Pharmacokinetics of Therapeutic Monoclonal Antibodies
Ron J. Keizer et al.
CLINICAL PHARMACOKINETICS (2010)
Fecal calprotectin is a predictive marker of relapse in Crohn's disease involving the colon: a prospective study
Lamia Kallel et al.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY (2010)
W1335 Previous Non-Response to Infliximab Predicts Early Dose-Escalation in Adalimumab Treated Crohn's Disease Patients
Evelien Bultman et al.
GASTROENTEROLOGY (2010)
Mucosal Healing Predicts Sustained Clinical Remission in Patients With Early-Stage Crohn's Disease
Filip Baert et al.
GASTROENTEROLOGY (2010)
Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis
C. H. Seow et al.
GUT (2010)
Predictive Value of Epithelial Gene Expression Profiles for Response to Infliximab in Crohn's Disease
Ingrid Arijs et al.
INFLAMMATORY BOWEL DISEASES (2010)
Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: Definitions, frequency and pharmacological aspects
Matthieu Allez et al.
JOURNAL OF CROHNS & COLITIS (2010)
Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease.
Jean Frederic Colombel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Early clinical experience with adalimumab in treatment of inflammatory bowel disease with infliximab-treated and naive patients
A. Swaminath et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2009)
Adalimumab for Crohn's disease with intolerance or lost response to infliximab: a 3-year single-centre experience
A. Oussalah et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2009)
Infliximab treatment for symptomatic Crohn's disease strictures
A. -L. Pelletier et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2009)
The efficacy and safety of a third anti-TNF monoclonal antibody in Crohn's disease after failure of two other anti-TNF antibodies
M. Allez et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2009)
Efficacy of Adalimumab in Moderate-to-Severe Pediatric Crohn's Disease
Franca Viola et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2009)
Loss of Response and Requirement of Infliximab Dose Intensification in Crohn's Disease: A Review
Javier P. Gisbert et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2009)
Long-term response rates to infliximab therapy for Crohn's disease in an outpatient cohort
Christopher W. Teshima et al.
CANADIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2009)
Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis
Adedigbo A. Fasanmade et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2009)
W1102 Anti-TNF Therapy for Crohn's Disease: Predictors of Dose Escalation and Early Discontinuation By 1 Year of Therapy
Amar S. Naik et al.
GASTROENTEROLOGY (2009)
T1215 Subanalysis of Remission Rates By Duration of Disease in Adalimumab-Treated Patients with Crohn's Disease: the Care Trial
Walter Reinisch et al.
GASTROENTEROLOGY (2009)
Influence of Trough Serum Levels and Immunogenicity on Long-term Outcome of Adalimumab Therapy in Crohn's Disease
Konstantinos Karmiris et al.
GASTROENTEROLOGY (2009)
Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort
F. Schnitzler et al.
GUT (2009)
IgG1 heavy chain-coding gene polymorphism (G1m allotypes) and development of antibodies-to-infliximab
Charlotte Magdelaine-Beuzelin et al.
PHARMACOGENETICS AND GENOMICS (2009)
Review: Predicting response to anti-TNF agents for the treatment of Crohn's disease
Corey A. Siegel et al.
Therapeutic Advances in Gastroenterology (2009)
Tumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn's disease
Mark A. Ainsworth et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2008)
Immunogenicity of anti-tumor necrosis factor antibodies - toward improved methods of anti-antibody measurement
Lucien Aarden et al.
CURRENT OPINION IN IMMUNOLOGY (2008)
Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease:: an open randomised trial
Geert D'Haens et al.
LANCET (2008)
Pharmacogenetics of Crohn's disease
Helga-Paula Toeroek et al.
PHARMACOGENOMICS (2008)
The use of adalimumab in the management of refractory Crohn's disease
G. -T. Ho et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2008)
Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial
W. J. Sandborn et al.
GUT (2007)
Maintenance therapy with certolizumab pegol for Crohn's disease
Stefan Schreiber et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Adalimumab induction therapy for Crohn disease previously treated with infliximab - A randomized trial
William J. Sandborn et al.
ANNALS OF INTERNAL MEDICINE (2007)
Predictive model for the outcome of infliximab therapy in Crohn's disease based on apoptotic pharmacogenetic index and clinical predictors
Tibor Hlavaty et al.
INFLAMMATORY BOWEL DISEASES (2007)
Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children
Jeffrey Hyams et al.
GASTROENTEROLOGY (2007)
Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial
Jean-Frederic Colombel et al.
GASTROENTEROLOGY (2007)
Polymorphism in IgG Fc receptor gene FCGR3A and response to infliximab in Crohn's disease: a subanalysis of the ACCENT I study
Edouard I. Louis et al.
PHARMACOGENETICS AND GENOMICS (2006)
Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease
Elana A. Maser et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2006)
Factors associated with the development of intestinal strictures or obstructions in patients with .Crohn's disease
Gary R. Lichtenstein et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2006)
Lymphotoxin alpha gene in Crohn's disease patients: absence of implication in the response to infliximab in a large cohort study
Vinciane Dideberg et al.
PHARMACOGENETICS AND GENOMICS (2006)
Infliximab plus azathioprine for steroid-dependent Crohn's disease patients:: A randomized placebo-controlled trial
M Lémann et al.
GASTROENTEROLOGY (2006)
Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial
SB Hanauer et al.
GASTROENTEROLOGY (2006)
No association between C-reactive protein gene polymorphisms and decrease of C-reactive protein serum concentration after infliximab treatment in Crohn's disease
S Willot et al.
PHARMACOGENETICS AND GENOMICS (2006)
Elimination mechanisms of therapeutic monoclonal antibodies
MA Tabrizi et al.
DRUG DISCOVERY TODAY (2006)
Multidrug resistance 1 gene polymorphisms are not associated with inflammatory bowel disease and response to therapy in Italian patients
O Palmieri et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2005)
Polymorphisms in apoptosis genes predict response to infliximab therapy in luminal and fistulizing Crohn's disease
T Hlavaty et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2005)
Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease
CA Solem et al.
INFLAMMATORY BOWEL DISEASES (2005)
Formation, distribution, and elimination of infliximab and anti-infliximab immune complexes in cynomolgus monkeys
JR Rojas et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2005)
IBD5 polymorphisms in inflammatory bowel disease: Association with response to infliximab
Elena Urcelay et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2005)
Association between polymorphism in IgG Fc receptor IIIa coding gene and biological response to infliximab in Crohn's disease
E Louis et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2004)
Infliximab maintenance therapy for fistulizing Crohn's disease
BE Sands et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Tumour necrosis factor-α receptor 1 and 2 polymorphisms in inflammatory bowel disease and their association with response to infliximab
M Pierik et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2004)
Incidence and Importance of Antibody Responses to Infliximab After Maintenance or Episodic Treatment in Crohn's Disease
Stephen B. Hanauer et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2004)
Fecal lactoferrin: A new parameter to monitor infliximab therapy
S Buderus et al.
DIGESTIVE DISEASES AND SCIENCES (2004)
Autoimmunity associated with anti-tumor necrosis factor α treatment in Crohn's disease:: A prospective cohort study
S Vermeire et al.
GASTROENTEROLOGY (2003)
An analysis of factors influencing short-term and sustained response to infliximab treatment for Crohn's disease
IDR Arnott et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2003)
Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease
F Baert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Response to infliximab treatment in Crohn's disease is not associated with mutations in the CARD15 (NOD2) gene:: an analysis in 534 patients from two multicenter, prospective GCP-level trials
S Mascheretti et al.
PHARMACOGENETICS (2002)
Strictures and response to infliximab in Crohn's disease
AM Weinberg et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2002)
Predictors of response to infliximab in patients with Crohn's disease
MA Parsi et al.
GASTROENTEROLOGY (2002)
NOD2/CARD15 does not influence response to infliximab in Crohn's disease
S Vermeire et al.
GASTROENTEROLOGY (2002)
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
SB Hanauer et al.
LANCET (2002)
ANCA pattern and LTA haplotype relationship to clinical responses to anti-TNF antibody treatment in Crohn's disease
KD Taylor et al.
GASTROENTEROLOGY (2001)
Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease
JA Tibble et al.
GASTROENTEROLOGY (2000)
Pretreatment with 6-mercaptopurine/azathioprine (6MP/AZA) prolongs clinical response time in Crohn's disease (CD) patients with fistulizing disease (FD) treated with infliximab (INF).
R Pittman et al.
GASTROENTEROLOGY (2000)
Treatment of Crohn's disease with Infliximab - An initial community practice experience.
RP McCabe et al.
GASTROENTEROLOGY (2000)
Share Paper
